Increased vascular angiotensin II binding capacity and ET-1 release in young cardiomyopathic hamsters.
Heart failure (HF) is a multifactorial and progressive disease that has been associated with multiple systemic and vascular alterations. Previous reports from our laboratory showed that in 2-month-old Bio-To2 Syrian cardiomyopathic hamsters (SCH) that have not yet developed the clinical manifestations of HF, the vascular contractility induced by 0.1 microM angiotensin II was approximately 35% greater than in control animals. This finding was observed concomitantly with an increased aortic ACE activity. To further evaluate the mechanisms underlying angiotensin II-enhanced vascular contraction, concentration-response curves for angiotensin II (0.01 nM-10 microM) were constructed before and after the addition of prazosin (alpha-1 blocker), NS-398 (selective COX-2 blocker) and BQ-123 (ET-1A-receptor antagonist) in aortic rings from 2-month-old SCH. The binding capacity and affinity of the AT-1 receptors were also evaluated in aortic homogenates using 125I-angiotensin II. Age-matched golden hamsters were used as controls (CT). Our results indicate that incubation with either 10 microM prazosin or 10 microM NS-398 did not modify EC50 or Emax values for angiotensin II indicating that norepinephrine and prostaglandins are not involved in the enhanced contractile action of angiotensin II. However, 10 microM BQ-123 reduced by 40% the contraction induced by 1.0 microM angiotensin II (from 1.05+/-0.04 to 0.6475+/-0.06 g/mg tissue, n = 5, P < 0.05), suggesting that in cardiomyopathic hamsters, the action of angiotensin II is mediated in part by ET-1. At lower angiotensin II concentration (0.1 microM), the ET-1-dependent contraction decreases to 29%. In addition, although dissociation constants for labeled angiotensin II were found to be similar in the aorta of SCH and control animals (K(D): CT = 7.8 nM and SCH = 5.1 nM), 125I-angiotensin II binding capacity was about 2-fold greater in SCH than in controls (Bmax: SCH = 1113 and CT = 605 fmol/mg protein). Altogether these results suggest that in 2-month-old SCH the enhanced response of angiotensin II in the vasculature is mediated both by an increased binding capacity for the hormone and facilitation of the ET-1 action.
Crespo
Maria J
MJ
Department of Physiology, University of Puerto Rico, School of Medicine, GPO Box 365067, San Juan, PR 00936-5067, Puerto Rico. mcrespo@rcm.upr.edu
Altieri
Pablo I
PI
Escobales
Nelson
N
D000804:Angiotensin II / Q000378:metabolism / Q000494:pharmacology*; D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects* / Q000378:metabolism; D001667:Binding, Competitive; D009202:Cardiomyopathies / Q000378:metabolism / Q000503:physiopathology*; D006224:Cricetinae; D004195:Disease Models, Animal; D018450:Disease Progression; D004305:Dose-Response Relationship, Drug; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D066298:In Vitro Techniques; D019808:Losartan / Q000494:pharmacology; D008297:Male; D008647:Mesocricetus; D010456:Peptides, Cyclic / Q000494:pharmacology; D011485:Protein Binding; D044140:Receptor, Angiotensin, Type 1 / Q000187:drug effects / Q000378:metabolism; D044022:Receptor, Endothelin A / Q000378:metabolism; D014661:Vasoconstriction; D014662:Vasoconstrictor Agents / Q000378:metabolism / Q000494:pharmacology*
D047228:Angiotensin II Type 1 Receptor Blockers; D065130:Endothelin A Receptor Antagonists; D019332:Endothelin-1; D010456:Peptides, Cyclic; D044140:Receptor, Angiotensin, Type 1; D044022:Receptor, Endothelin A; D014662:Vasoconstrictor Agents; D000804:Angiotensin II; D019808:Losartan; C072247:cyclo(Trp-Asp-Pro-Val-Leu)